Drawing for TARPIXIS

USPTO serial 87650750

TARPIXIS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CARLYLE, SHAUNIA P
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TARPIXIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Claudia A. Smith

CLAUDIA A. SMITH WHITE & CASE LLP1221 AVENUE OF THE AMERICASTRADEMARK DEPARTMENTNEW YORK, NY 10020

Goods and services

ClassDescriptionStatusFirst use
005(Based on 44(d) Priority Application) (Based on Intent to Use) Vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases in, generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy; pharmaceutical preparations and substances for the prevention and treatment of Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; diagnostic agents, reagents, preparations and substances for medical purposesACTIVE—
010(Based on 44(d) Priority Application) (Based on Intent to Use) Medical apparatus and instruments for use in diagnosing and monitoring vital signs of patients with psychiatric and neurological disorders and diseases, dementia, Alzheimer's disorder and disease, dizziness, seizures, stroke, depression, cognitive impairment, cognitive disorders and diseases, mood disorders, psychosis, anxiety, apathy, epilepsy, Lennox-Gastaut syndrome (LGS), sclerosis, porphyria, Huntington's disorder and disease, insomnia, Parkinson's disorder and disease, falls, movement disorders and diseases, tremor, schizophrenia, bipolar disorder and disease, mania, ADHD, PTSD, agitation, aggression, autism, melancholy, OCD, Tourette's syndrome, progressive supranuclear palsy (PSP), restlessness, akathisia, fatigue, somnolence, nausea, cancer, migraine, pain, alcoholism and dependency; injection devices for pharmaceuticals, syringes and needles for injections and medical purposes; integrated medical systems, namely, medical diagnostic imaging apparatus and software sold as a unit therewith for managing, measuring, monitoring, assessing, controlling, collecting, storing and examining patient and client data and information captured by the medical system in web-based physical, psychological and neurological examinations conducted at a distance and at a clinic; medical apparatus and units for dosage, measuring and monitoring, namely, drug delivery devices and systemsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Aug 19, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 19, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 25, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 21, 2018EX1GSOU EXTENSION 1 GRANTED—
Dec 21, 2018EXT1SOU EXTENSION 1 FILED—
Dec 21, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 17, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 22, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 22, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 2, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 13, 2018FIXDELECTRONIC RECORD REVIEW COMPLETE—
Mar 30, 2018ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Mar 26, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 26, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Mar 26, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 26, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 26, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 15, 2018GAUNNOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED—
Mar 15, 2018GAUDNOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED—
Mar 15, 2018NAUDREPORT UNRESPONSIVE AMENDMENT - COMPLETED—
Feb 22, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 22, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 16, 2018ALIEASSIGNED TO LIE—
Feb 9, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 29, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 29, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 29, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 26, 2018DOCKASSIGNED TO EXAMINER—
Oct 27, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 21, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance